Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Cancer Science|March 25, 2022
Two-year outcomes of tirabrutinib monotherapy in Waldenström's macroglobulinemiaNaohiro Sekiguchi, Shinya Rai, Wataru Munakata, et al.
Cancer Science|July 9, 2020
A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemiaNaohiro Sekiguchi, Shinya Rai, Wataru Munakata, et al.
Cancer Science|December 21, 2021
Phase 1/2 study evaluating the safety and efficacy of DSP-7888 dosing emulsion in myelodysplastic syndromesYasunori Ueda, Kensuke Usuki, Jiro Fujita, et al.
Cancer Science|December 22, 2005
Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphomaTakashi Watanabe, Shoji Terui, Kuniaki Itoh, et al.
International Journal of Hematology|January 7, 2003
Intensified daunorubicin in induction therapy and autologous peripheral blood stem cell transplantation in postremission therapy (Double-7 protocol) for adult acute myeloid leukemiaNoriko Usui, Nobuaki Dobashi, Osamu Asai, et al.
BMC Cancer|October 9, 2012
Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphomaJunko Nomoto, Nobuhiro Hiramoto, Motohiro Kato, et al.
Seminars in Hematology|May 25, 2025
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom's MacroglobulinemiaShayna Sarosiek, Anne-Marie L Becking, Andrew Branagan, et al.
Ejhaem|July 18, 2022
Phase II study of dose-adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B-cell lymphoma patientsSatoshi Yamasaki, Akiko Kada, Ilseung Choi, et al.
International Journal of Hematology|February 27, 2025
Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351Hideki Makishima, Taisuke Mikasa, Kento Isogaya, et al.
Leukemia & Lymphoma|June 23, 2025
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapyJohn Kuruvilla, Dipenkumar Modi, Armando Santoro, et al.
Pageof 6